Phaseline

Targets › GHR

GHR (Growth hormone receptor): drug programs, companies and trials

7 programs from 7 companies in 19 trials: 9 Phase 2, 7 Phase 3, 2 Phase 4, 1 Phase 1; Other, Metabolic and endocrine, Neurology; next expected readout Dec 2026.

Receptor for pituitary gland growth hormone (GH1) involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway..; FUNCTION: [Growth hormone-binding protein]: The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling..; FUNCTION: [Isoform 2]: Up-regulates the production of the soluble Growth hormone-binding protein…. (UniProt, P10912)

Open in Phaseline: the race on GHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Changchun GeneScience PharmaceuticalSomatropin
Growth hormone receptor agonist
GHRPhase 4Short Bowel Syndrome (SBS) in Adults; Short Stature Children Born Small for Gestational Age (SGA); Dwarfism; Healthy …Apr 2027
Novo NordiskSomapacitan
Growth hormone receptor agonist
GHRPhase 3SGA, Turner Syndrome, Noonan Syndrome, ISS; SGA; Short Stature Children Born Small for Gestational Age (SGA)Dec 2026
Rabin Medical CenterSomatrogon
Growth hormone receptor agonist
GHRPhase 3ISSDec 2027
Ascendis PharmaLonapegsomatropin
Growth hormone receptor agonist
GHRPhase 3Turner SyndromeFeb 2028
Ascendis Pharma Growth DisordersLonapegsomatropin
Growth hormone receptor agonist
GHRPhase 2AchondroplasiaNov 2027
Ascendis Pharma Endocrinology DivisionLonapegsomatropin
Growth hormone receptor agonist
GHRPhase 2Turner SyndromeDec 2027
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Pegvisomant
Growth hormone receptor antagonist
GHRPhase 2Insulin Receptor MutationJan 2028

Conditions

Short Stature Children Born Small for Gestational Age (SGA) (2) Growth Disorders (2) Turner Syndrome (2) SGA, Turner Syndrome, Noonan Syndrome, ISS (1) SGA (1) Short Bowel Syndrome (SBS) in Adults (1) Dwarfism (1) Healthy (1) Preimplantation Genetic Testing (1) Adult Growth Hormone Deficiency (1) Infertility (1) Gulf War Syndrome (1)

Modalities

protein or peptide (4), small molecule (2), mixed (1)

Companies

Novo Nordisk (1) Changchun GeneScience Pharmaceutical (1) Ascendis Pharma Growth Disorders (1) Ascendis Pharma Endocrinology Division (1) Rabin Medical Center (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Ascendis Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.